Omega-3 Fatty Acids and Cardiovascular Disease: New Developments and Applications

References

• . Pan A, Chen M, Chowdhury R, . Alpha-linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96:1262–1273
   PubMed Web of Science ®Google Scholar
• . Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: Implications for their essentiality and use as supplements. Appl Physiol Nutrition Metabol. 2007;32:619–34
   PubMed Web of Science ®Google Scholar
• . De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med. 2011;364:2439–2450
   PubMed Web of Science ®Google Scholar
• . Saravanan P, Davidson NC, Schmidt EB, . Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376:540–550
   PubMed Web of Science ®Google Scholar
• . Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways and clinical events. J Am Coll Cardiol. 2011;58:2047–2067
   PubMed Web of Science ®Google Scholar
• . Kromhout D, Yasuda S, Geleijnse JM, . Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 2012;33:436–443
   PubMed Web of Science ®Google Scholar
• . Lavie CJ, Milani RV, Mehra MR, . Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54:585–594
   PubMed Web of Science ®Google Scholar
• . Rizos EC, Ntzani EE, Bika E, . Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024–1033
   PubMed Web of Science ®Google Scholar
• . Kwak SM, Myung SK, Lee YJ, . Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686–694
   PubMed Web of Science ®Google Scholar
• . Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, . Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012;107( Suppl 2):S201–S213
   PubMed Web of Science ®Google Scholar
• . Trikalinos TA, Lee J, Moorthy D, . Effects of eicosapentaenoic acid and docosahexaenoic acid on mortality across diverse settings: systematic review and meta-analysis of randomized trials and prospective cohorts. Rockville, MD: AHRQ Publication No. 12-EHC040-EF; 2012
   Google Scholar
• . Roncaglioni MC, Tombesi M, Avanzini F, . n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800–1808
   PubMed Web of Science ®Google Scholar
• . Burr ML, Fehily AM, Gilbert JF, . Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757–761
   PubMed Web of Science ®Google Scholar
• . Marchioli R, Barzi F, Bomba E, . Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per 1o Studio della Soprawivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–1903
   PubMed Web of Science ®Google Scholar
• . Yokoyama M, Origasa H, Matsuzaki M, . Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098
   PubMed Web of Science ®Google Scholar
• . Kotwal S, Jun M, Sullivan D, . Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5:808–818
   PubMed Web of Science ®Google Scholar
• . GISSI-HF I. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–1230
   PubMedGoogle Scholar
• . Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–2026
   PubMed Web of Science ®Google Scholar
• . Bosch J, Gerstein HC, Dagenais GR, . n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–318
   PubMed Web of Science ®Google Scholar
• . Raitt MH, Connor WE, Morris C, . Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293:2884–2891
   PubMed Web of Science ®Google Scholar
• . Brouwer IA, Raitt MH, Dullemeijer C, . Effect offish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J. 2009;30:820–826
   PubMed Web of Science ®Google Scholar
• . Leaf A, Albert CM, Josephson M, . Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112:2762–2768
   PubMed Web of Science ®Google Scholar
• . Sacks FM, Stone PH, Gibson CM, . Controlled trial offish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol. 1995;25:1492–1498
   PubMed Web of Science ®Google Scholar
• . von Schacky C, Angerer P, Kothny W, . The effect of dietary ω-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;130:554–562
   PubMed Web of Science ®Google Scholar
• . Garbagnati F, Cairella G, De Martino A, . Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke Trial. Cerebrovasc Dis (Basel). 2009;27:375–383
   PubMedGoogle Scholar
• . Rauch B, Schiele R, Schneider S, . OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152–159
   PubMed Web of Science ®Google Scholar
• . Itomura M, Fujioka S, Hamazaki K, . Factors influencing EPA+DHA levels in red blood cells in Japan. In vivo (Athens, Greece). 2008;22:131–135
   PubMed Web of Science ®Google Scholar
• . ASCEND—A Study of Cardiovascular Events in Diabetes, http://clinicaltrials.gov/ct2/show/NCT00135226?term=ascend+aspirin+omega-3&rank=l. Accessed October 2, 2013
   Google Scholar
• . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). 2012. http://clinicaltrials.gov/show/NCT01492361. Accessed October 2, 2013
   Google Scholar
• . Harris WS, Ginsberg HN, Arunakul N, . Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385–392
   PubMedGoogle Scholar
• . Bays HE, Ballantyne CM, Kastelein JJ, . Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, p1Acebo-controlled, Randomized, double-b1INd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682–690
   PubMed Web of Science ®Google Scholar
• . Pownall HJ, Brauchi D, Kilinc C, . Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285–297
   PubMed Web of Science ®Google Scholar
• . Davidson MH, Stein EA, Bays HE, . Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/dto simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354–1367
   PubMed Web of Science ®Google Scholar
• . Ballantyne CM, Bays HE, Kastelein JJ, . Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–992
   PubMed Web of Science ®Google Scholar
• . Sadovsky R, Kris-Etherton P. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides. Postgrad Med. 2009;121:145–153
   PubMed Web of Science ®Google Scholar
• . Tatsuno I, Saito Y, Kudou K, Ootake J. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol. 2013;7(3):199–207
   PubMed Web of Science ®Google Scholar
• . Sullivan DR, Sanders TAB, Trayner IM, . Paradoxical Elevation of LDL Apoprotein B Levels in Hypertriglyceridaemic Patients and Normal Subjects Ingesting Fish Oil. Atherosclerosis. 1986;61:129–134
   PubMed Web of Science ®Google Scholar
• . Harris WS, Dujovne CA, Zucker M, . Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients: a placebo-controlled trial. Ann Intern Med. 1988;109:465–470
   PubMed Web of Science ®Google Scholar
• . Eslick GD, Howe PR, Smith C, . Benefits offish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136:4–16
   PubMed Web of Science ®Google Scholar
• . Goldberg AC, Schonfeld G, Feldman EB, . Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Clin Ther. 1989;11:69–83
   PubMed Web of Science ®Google Scholar
• . Harris WS, Windsor SL, Caspermeyer JJ. Modification of lipid-related atherosclerosis risk factors by w3 fatty acid ethyl esters in hypertriglyceridemic patients. J Nutr Biochem. 1993;4:706–712
   Google Scholar
• . Maki KC, Van Elswyk ME, McCarthy D, . Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005;24:189–199
   PubMed Web of Science ®Google Scholar
• . Maki KC, Bays HE, Dicklin MR, . Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol. 2011;5:483–492
   PubMed Web of Science ®Google Scholar
• . Neff LM, Culiner J, Cunningham-Rundles S, . Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr. 2011;141:207–213
   PubMed Web of Science ®Google Scholar
• . Calabresi L, Donati D, Pazzucconi F, . Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000;148:387–396
   PubMed Web of Science ®Google Scholar
• . Harris WS, Miller M, Tighe AP, . Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197:12–24
   PubMed Web of Science ®Google Scholar
• . Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res. 2012;53:2525–2545
   PubMed Web of Science ®Google Scholar
• . Shearer GC, Newman JW. Impact of circulating esterified eicosanoids and other oxylipins on endothelial function. Curr Atheroscler Rep. 2009;11:403–410
   PubMedGoogle Scholar
• . Arnold C, Markovic M, Blossey K, . Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J Biol Chem. 2010;285(43):32720–32733
   PubMed Web of Science ®Google Scholar
• . Wada M, Delong CJ, Hong YH, . Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem. 2007;282:22254–22266
   PubMed Web of Science ®Google Scholar
• . Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011;111:5922–5943
   PubMed Web of Science ®Google Scholar
• . Jump DB. Fatty acid regulation of hepatic lipid metabolism. Curr Opin Clin Nutr Metab Care. 2011;14:115–120
   PubMed Web of Science ®Google Scholar
• . Balk EM, Lichtenstein AH, Chung M, . Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189:19–30
   PubMed Web of Science ®Google Scholar
• . Geleijnse JM, Giltay EJ, Grobbee DE, . Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20:1493–1499
   PubMed Web of Science ®Google Scholar
• . Violi F, Pignatelli P, Basili S. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation. 2010;121:1033–1044
   PubMedGoogle Scholar
• . Mozaffarian D, Geelen A, Brouwer IA, . Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation. 2005;112:1945–1952
   PubMed Web of Science ®Google Scholar
• . Rauch B, Senges J. The effects of supplementation with omega-3 polyunsaturated Fatty acids on cardiac rhythm: anti-arrhythmic, pro-arrhythmic, both or neither? It depends.. Front Physiol. 2012;3:57
   PubMedGoogle Scholar
• . Cawood AL, Ding R, Napper FL, . Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252–259
   PubMed Web of Science ®Google Scholar
• . Thies F, Garry JM, Yaqoob P, . Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361:477–485
   PubMed Web of Science ®Google Scholar
• . Pase MP, Grima NA, Sarris J. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br J Nutr. 2011;106:974–980
   PubMed Web of Science ®Google Scholar
• . Mariani J, Doval HC, Nul D, . N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2013;2(1):e005033
   PubMed Web of Science ®Google Scholar
• . Mozaffarian D, Marchioli R, Macchia A, ; OPERA Investigators. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA. 2012;308(19):2001–2011
   PubMed Web of Science ®Google Scholar
• . Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757
   PubMed Web of Science ®Google Scholar
• . Mosca L, Benjamin EJ, Berra K, . Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243–1262
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services. US Department of Health. Dietary Guidelines for Americans 2010. http://health.gov/dietaryguidelines/dga2010/dietaryguidelines2010.pdf. Accessed October 3, 2013
   Google Scholar
• . Kris-Etherton PM, Innis S. Position of the American Dietetic Association and Dietitians of Canada: Dietary Fatty Acids. J Am Diet Assoc. 2007;107:1599–1611
   PubMed Web of Science ®Google Scholar
• . Recommendations for intake of polyunsaturated fatty acids in healthy adults. International Society for the Study of Fatty Acids and Lipids, 2004. http://www.issfal.org/news-links/resources/publications/PUFAIntakeReccomdFinalReport.pdf. Accessed October 3, 2013
   Google Scholar
• . Gillies PJ, Harris WS, Kris-Etherton PM. Omega-3 fatty acids in food and pharma: the enabling role of biotechnology. Curr Atheroscler Rep. 2011;13:467–473
   PubMedGoogle Scholar
• . Harris WS. Stearidonic acid-enhanced soybean oil: a plant-based source of (n-3) fatty acids for foods. J Nutr. 2012;142:600S–604S
   PubMed Web of Science ®Google Scholar
• . Harris WS. Stearidonic acid as a ‘pro-eicosapentaenoic acid’. Curr Opin Lipidol. 2012;23:30–34
   PubMedGoogle Scholar
• . Davidson MH, Kling D, Maki KC. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol. 2011;22:437–444
   PubMed Web of Science ®Google Scholar
• . Neubronner J, Schuchardt JP, Kressel G, . Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur J Clin Nutr. 2011;65:247–254
   PubMed Web of Science ®Google Scholar
• . Dyerberg J, Madsen P, Moller JM, . Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010;83:137–141
   PubMed Web of Science ®Google Scholar
• . Ulven SM, Kirkhus B, Lamglait A, . Metabolic effects of krill oil are essentially similar to those offish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011;46:37–46
   PubMed Web of Science ®Google Scholar
• . Maki KC, Reeves MS, Farmer M, . Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res. 2009;29:609–615
   PubMed Web of Science ®Google Scholar
• . Harris WS, Pottala JV, Sands SA, . Comparison of the effects of fish and fish-oil capsules on then 3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr. 2007;86:1621–1625
   PubMed Web of Science ®Google Scholar
• . Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietary Products, 2012. http://www.efsa.europa.eu/en/efsajournal/doc/2815.pdf. Accessed October 3, 2013
   Google Scholar
• . Brasky TM, Darke AK, Song X, . Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013;105(15):1132–1141
   PubMed Web of Science ®Google Scholar
• . Brasky TM, Kristal AR, Navarro SL, . Specialty supplements and prostate cancer risk in the VTTamins and Lifestyle (VITAL) cohort. Nutr Cancer. 2011;63(4):573–582
   PubMed Web of Science ®Google Scholar
• . Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr. 2010;92:1223–1233
   PubMed Web of Science ®Google Scholar
• . Terry P, Lichtenstein P, Feychting M, . Fatty fish consumption and risk of prostate cancer. Lancet. 2001;357:1764–1766
   PubMed Web of Science ®Google Scholar
• . Leitzmann MF, Stampfer MJ, Michaud DS, . Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr. 2004;80:204–216
   PubMed Web of Science ®Google Scholar
• . Mina K, Fritschi L, Johnson KC. An inverse association between preserved fish and prostate cancer: results from a population-based case-control study in Canada. Nutr Cancer. 2008;60:222–226
   PubMed Web of Science ®Google Scholar
• . Epstein MM, Kasperzyk JL, Mucci LA, . Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. Am J Epidemiol. 2012;176:240–252
   PubMed Web of Science ®Google Scholar
• . Fradet V, Cheng I, Casey G, . Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res. 2009;15:2559–2566
   PubMed Web of Science ®Google Scholar
• . Omega-3 Oils: Fish or Pills? Consumers Union, 2003. http://www.accessmylibrary.com/coms2/summary_0286-23726262_ITM. Accessed October 3, 2013
   Google Scholar
• . Fish-oil Pills vs Claims. Consumer Reports, 2012. http://www.consumerreports.org/cro/magazine/2012/01/fish-oil-pills-vs-claims/index.htm. Accessed October 2, 2013
   Google Scholar
• . Koletzko B, Lien E, Agostoni C, . The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med. 2008;36:5–14
   PubMed Web of Science ®Google Scholar
• . Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39:212–220
   PubMed Web of Science ®Google Scholar
• . Harris WS, Sands SA, Windsor SL, . Omega-3 fatty acids in cardiac biopsies from heart transplant patients: correlation with erythrocytes and response to supplementation. Circulation. 2004;110:1645–1649
   PubMed Web of Science ®Google Scholar
• . Harris WS, Thomas RM. Biological variability of blood omega-3 biomarkers. Clin Biochem. 2010;43:338–340
   PubMed Web of Science ®Google Scholar
• . Harris WS, Varvel SA, Pottala JV, . Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: Implications for clinical utility. J Clin Lipidol. 2013;7:433–440
   PubMed Web of Science ®Google Scholar
• . Pottala JV, Garg S, Cohen BE, . Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: The Heart and Soul Study. Circ Cardiovasc Qual Outcomes. 2010;3:406–412
   PubMed Web of Science ®Google Scholar
• . Shearer GC, Pottala JV, Spertus JA, . Red blood cell fatty acid patterns and acute coronary syndrome. PloS One. 2009;4:e5444
   Google Scholar
• . Harris WS. The omega-3 index: clinical utility for therapeutic intervention. Curr Cardiol Rep. 2010;12(6):503–508
   PubMedGoogle Scholar
• . Harris WS. The omega-3 index: from biomarker to risk marker to risk factor. Curr Atheroscler Rep. 2009;11:411–417
   PubMed Web of Science ®Google Scholar
• . Block RC, Harris WS, Reid KJ, . EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis. 2007;197:821–828
   PubMedGoogle Scholar
• . Farzaneh-Far R, Lin J, Epel ES, . Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA. 2010;303:250–257
   PubMed Web of Science ®Google Scholar
• . Johnston DT, Deuster PA, Harris WS, . Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed U.S. Servicemembers. Nutr Neurosci. 2013;16:30–38
   PubMed Web of Science ®Google Scholar
• . Tan ZS, Harris WS, Beiser AS, . Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology. 2012;78:658–664
   PubMed Web of Science ®Google Scholar
• . Farzaneh-Far R, Harris WS, Garg S, . Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis. 2009;205:538–543
   PubMed Web of Science ®Google Scholar
• . von Schacky C. Use of red cell fatty acid profiles as biomarkers in cardiac disease. Biomark Med. 2009;3:25–32
   PubMed Web of Science ®Google Scholar
• . Harris WS, Pottala JV, Lacey SM, . Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis. 2012;225:425–431
   PubMed Web of Science ®Google Scholar
• . Harris WS, Pottala JV, Varvel SA, . Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: Observations from 160,000 patients. Prostagland Leukot Essent Fatty Acids. 2013;88:257–263
   PubMed Web of Science ®Google Scholar
• . Berglund L, Brunzell JD, Goldberg AC, . Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–2989
   PubMed Web of Science ®Google Scholar
• . Miller M, Stone NJ, Ballantyne C, . Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–2333
   PubMed Web of Science ®Google Scholar
• . Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. Adv Nutr Res. 1980;3:1–22
   Google Scholar
• . Nutrient Reference Values for Australia and New Zealand. 2005. http://www.nhmrc.gov.au/publications/synopses/n35syn.htm. Accessed October 2, 2013
   Google Scholar
• . USDA Agricultural Research Center, Nutrient Data Laboratory. 2012. http://ndb.nal.usda.gov/ndb/search/list. Accessed September 2, 2013
   Google Scholar